Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234224 | 0.94 | MAPT (0.50) | MAPTTDP1RAB9AHSP90AA1HTT | |
| SCHEMBL385093 | 0.89 | MAPT (0.51) | MAPTTDP1L3MBTL1RAB9AINPPL1 | |
| SCHEMBL16482859 | 0.87 | MAOA (0.54) | MAPTTDP1L3MBTL1HSP90AA1HTT | |
| SCHEMBL28519834 | 0.87 | TDP1 (0.51) | MAPTTDP1L3MBTL1KDM4EMAOA | |
| SCHEMBL3900807 | 0.86 | CA12 (0.60) | MAPTL3MBTL1RAB9AMAOBTP53 | |
| SCHEMBL20982560 | 0.86 | MAPT (0.56) | MAPTTDP1L3MBTL1RAB9AHTT | |
| SCHEMBL27009298 | 0.85 | ALDH1A1 (0.54) | MAPTL3MBTL1INPPL1KDM4EALDH1A1 | |
| SCHEMBL4447935 | 0.85 | LMNA (0.51) | MAPTL3MBTL1INPPL1KDM4EMAOB | |
| SCHEMBL25344842 | 0.84 | FFAR4 (0.57) | MAPTTDP1L3MBTL1RAB9AHSP90AA1 | |
| SCHEMBL257677 | 0.84 | TDP1 (0.46) | MAPTTDP1L3MBTL1RAB9AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240019746-A1 | ULTRA-HIGH-POLARITY CHIRAL LIQUID CRYSTAL MATERIAL, LIQUID CRYSTAL LASER AND PREPARATION METHOD THEREFOR | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240019746-A1 | ULTRA-HIGH-POLARITY CHIRAL LIQUID CRYSTAL MATERIAL, LIQUID CRYSTAL LASER AND PREPARATION METHOD THEREFOR | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240019746-A1 | ULTRA-HIGH-POLARITY CHIRAL LIQUID CRYSTAL MATERIAL, LIQUID CRYSTAL LASER AND PREPARATION METHOD THEREFOR | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2024-01-18 | — | — | US | disclosed |
| WO-2022089501-A1 | ULTRA-HIGH-POLARITY CHIRAL LIQUID CRYSTAL MATERIAL, LIQUID CRYSTAL LASER AND PREPARATION METHOD THEREFOR | 华南理工大学 | 2022-05-05 | — | — | WO | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-1948617-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007048065-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK1A1, CSNK2A2 | MAPT 1859/4885TDP1 2331/4885L3MBTL1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.